Reuters logo
BRIEF-Blueprint Medicines Q3 loss per share $0.96
October 31, 2017 / 11:14 AM / 22 days ago

BRIEF-Blueprint Medicines Q3 loss per share $0.96

Oct 31 (Reuters) - Blueprint Medicines Corp

* Blueprint Medicines reports third quarter 2017 financial results

* Q3 loss per share $0.96

* Q3 earnings per share view $-0.91 -- Thomson Reuters I/B/E/S

* Blueprint Medicines - ‍existing cash will be sufficient to fund its operating expenses and capex requirements into H2 2019​

* Blueprint Medicines - ‍plans to initiate a global, pivotal Phase 3 clinical trial of BLU-285 in third-line patients with KIT-driven GIST in H1 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below